Novabay Pharmaceuticals, INC Schedule 13D activist filings

Framework Ventures IV L.P. and associated entities have increased their beneficial ownership in Stablecoin Development Corp to 46.7% following the vesting of pre-funded warrants.

R01 Fund LP and associated entities have increased their beneficial ownership in Stablecoin Development Corp to 48.4% following the vesting of pre-funded warrants.

Sky Frontier Foundation updates its Schedule 13D filing to reflect a change in beneficial ownership percentage due to an increase in Stablecoin Development Corp's outstanding shares.

Framework Ventures IV L.P. has increased its beneficial ownership in Stablecoin Development Corp to 45.9% following the full cashless exercise of pre-funded warrants.

R01 Fund LP and associated entities have increased their beneficial ownership in Stablecoin Development Corp to 49.8% following a full cashless exercise of pre-funded warrants.

Sky Frontier Foundation has acquired a pre-funded warrant for 100,000,000 shares of Stablecoin Development Corp, representing a 9.99% beneficial ownership.

Framework Ventures IV L.P. filed an amendment to its Schedule 13D disclosing a 46.4% beneficial ownership stake in Stablecoin Development Corp following the vesting of pre-funded warrants.

R01 Fund LP and Michael Kazley filed an amendment to their Schedule 13D, reporting a change in beneficial ownership due to the vesting of pre-funded warrants.

R01 Fund LP and Michael Kazley updated their beneficial ownership in Stablecoin Development Corp following anti-dilution warrant adjustments.

Framework Ventures reports a 44.5% beneficial ownership stake in Stablecoin Development Corp following warrant adjustments and a reverse stock split.

R01 Fund LP and associated entities have updated their Schedule 13D filing, reporting a combined beneficial ownership of 58.1% of Stablecoin Development Corp's common stock, including newly granted restricted stock units to Michael Kazley.

David E. Lazar has filed an exit amendment for his Schedule 13D, reporting a 4.99% beneficial ownership in NovaBay Pharmaceuticals, Inc. following the conversion of preferred stock.

Framework Ventures IV L.P. and its affiliates have increased their beneficial ownership in NovaBay Pharmaceuticals, Inc. to 45.0% and secured rights to appoint a director.

R01 Fund LP and its affiliates, forming a group with Framework Ventures, increased their beneficial ownership in NovaBay Pharmaceuticals to 45% and secured the right to appoint a director.

R01 Fund LP and its affiliates increased their beneficial ownership in NovaBay Pharmaceuticals, Inc. to 45.1% through the conversion of Series D preferred stock and the acquisition of new Series E preferred stock.

Framework Ventures IV L.P. and its affiliates have increased their beneficial ownership in NovaBay Pharmaceuticals, Inc. to 45.1% through convertible preferred stock and a pre-funded warrant.

David E. Lazar, NovaBay Pharmaceuticals' CEO and director, has sold a significant portion of his preferred stock and rights to new investors, resigning from his roles.

NovaBay Pharmaceuticals, Inc. has terminated its voting agreement with Poplar Point Capital Management LLC and its affiliates, effective upon a recent vote, granting Poplar Point greater flexibility in managing its 17.52% stake.

R01 Fund LP and Framework Ventures IV L.P. acquired $12 million in NovaBay Pharmaceuticals preferred stock from CEO David Lazar, with R01 Fund LP's beneficial ownership reaching 16.2%.

Framework Ventures IV L.P. and R01 Fund LP have acquired a significant stake in NovaBay Pharmaceuticals, Inc., injecting $2.15 million into the company as part of a plan to address NYSE listing deficiencies.

NovaBay Pharmaceuticals has entered into a voting agreement with a significant shareholder group, facilitating a potential capital raise and a special cash dividend.

David E. Lazar has been appointed CEO and a director of NovaBay Pharmaceuticals, Inc., following a $3.85 million investment and an agreement for an additional $2.15 million, significantly increasing his stake to 19.99%.

Poplar Point Capital Management and its affiliates have reported a beneficial ownership of 17.54% of Novabay Pharmaceuticals, Inc.'s common stock, acquired for investment purposes with potential for control.